Astellas Pharma Inc (ALPMY)
10.70
0.00 (0.00%)
USD |
OTCM |
Nov 15, 16:00
Astellas Pharma Net Income (Quarterly): 241.22M for June 30, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
Date | Value |
---|---|
June 30, 2024 | 241.22M |
March 31, 2024 | -224.22M |
December 31, 2023 | 98.29M |
September 30, 2023 | -10.10M |
June 30, 2023 | 241.43M |
March 31, 2023 | -349.20M |
December 31, 2022 | 343.34M |
September 30, 2022 | 518.47M |
June 30, 2022 | 191.49M |
March 31, 2022 | -72.38M |
December 31, 2021 | 535.60M |
September 30, 2021 | 371.79M |
June 30, 2021 | 280.35M |
March 31, 2021 | -116.40M |
December 31, 2020 | 575.24M |
September 30, 2020 | 211.30M |
June 30, 2020 | 468.48M |
March 31, 2020 | 49.49M |
December 31, 2019 | 565.52M |
September 30, 2019 | 652.70M |
June 30, 2019 | 532.42M |
March 31, 2019 | 279.05M |
December 31, 2018 | 777.62M |
September 30, 2018 | 442.37M |
June 30, 2018 | 500.22M |
Date | Value |
---|---|
March 31, 2018 | 203.55M |
December 31, 2017 | 535.66M |
September 30, 2017 | 357.46M |
June 30, 2017 | 382.23M |
March 31, 2017 | 350.91M |
December 31, 2016 | 584.04M |
September 30, 2016 | 473.37M |
June 30, 2016 | 616.77M |
March 31, 2016 | 252.91M |
December 31, 2015 | 507.22M |
September 30, 2015 | 477.26M |
June 30, 2015 | 367.85M |
March 31, 2015 | 177.19M |
December 31, 2014 | 391.39M |
September 30, 2014 | 328.30M |
June 30, 2014 | 351.05M |
March 31, 2014 | 72.12M |
December 31, 2013 | 377.38M |
September 30, 2013 | 260.24M |
June 30, 2013 | 200.76M |
March 31, 2013 | 85.00M |
December 31, 2012 | 335.36M |
September 30, 2012 | 278.71M |
June 30, 2012 | 442.74M |
March 31, 2012 | -257.16M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-349.20M
Minimum
Mar 2023
575.24M
Maximum
Dec 2020
206.30M
Average
241.22M
Median
Jun 2024
Net Income (Quarterly) Benchmarks
Pfizer Inc | 4.465B |
Takeda Pharmaceutical Co Ltd | 619.69M |
Nxera Pharma Co Ltd | 8.079M |
PeptiDream Inc | 120.39M |
Healios KK | -3.426M |
Net Income (Quarterly) Related Metrics
Revenue (Quarterly) | 3.035B |
Total Expenses (Quarterly) | 2.728B |
EPS Diluted (Quarterly) | 0.1343 |
Enterprise Value | 23.34B |
Gross Profit Margin (Quarterly) | 80.74% |
Profit Margin (Quarterly) | 7.95% |
Earnings Yield | 0.54% |
Operating Earnings Yield | 0.54% |
Normalized Earnings Yield | 0.2548 |